It is considered that downregulation of this signalling pathway, which mediates tumour cell proliferation and survival, is important for anti-proliferative effects of therapeutic agents targeting the epidermal growth factor receptors [12], [13], [14]. The gene discussed is EGFR; the disease is neoplasm.